Hematopoiesis is prognostic for toxicity and survival of Radium treatment in patients with metastatic castration-resistant prostate cancer.

Journal: Hellenic journal of nuclear medicine

PMID: 29324927

Abstract

OBJECTIVE: We evaluated the impact of pre-therapeutic hematopoiesis on survival, hematotoxicity (HT) and number of Radium (Ra) treatments in patients with metastatic castration-resistant prostate cancer.

Authors

A Leisser

Department of Biomedical Imaging and Image-guided Therapy Medical University, Vienna 1090, Vienna, Austria. asha.leisser@meduniwien.ac.at.
M Nejabat
M Hartenbach
H Duan
S F Shariat
G Kramer
M Krainer
M Hacker
A R Haug

Keywords

Adult Aged Hematopoiesis Humans Male Middle Aged Neoplasm Grading Neoplasm Metastasis Prognosis Prostatic Neoplasms, Castration-Resistant Radium Survival Analysis

External Resources

View on PubMed PubMed (29324927)

Hematopoiesis is prognostic for toxicity and survival of Radium treatment in patients with metastatic castration-resistant prostate cancer.

Abstract

Authors

Keywords

External Resources

Popular Topics

Recent Journals